Magnesium Treatment in Hypoparathyroidism

University of Tartu10 enrolled

Overview

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypoparathyroidism

Interventions

magnesiumDIETARY_SUPPLEMENT

magnesium 350 mg tablets once a day for 3 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * primary or secondary hypoparathyroidism * treatment with calcium plus vitamin D analogue * ionized calcium 1,0-1,29 mmol/L * magnesium level 0,7-1,05 mmol/L * TSH 0.1- 10 imU/L Exclusion Criteria: * any other disease known to influence plasma Ca level * pregnancy * creatinine \> 150 microM/L * patient has used supplementary magnesium within 2 previous months

Locations (1)

Tartu University Hospital

Tartu, Estonia

Outcomes

Primary Outcomes

Calcium level at the end of magnesium treatment compared to pretreatment level

Time frame: 3 weeks

Secondary Outcomes

Calcium level after stopping treatment compared to the level at the end of magnesium treatment

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.